中国骨质疏松杂志

强直性脊柱炎合并骨质疏松症的治疗研究进展

Advances in the treatment of ankylosing spondylitis with osteoporosis

DOI：10.3969/j.issn.1006.7108.2022.03.025

英文关键词:ankylosing spondylitis osteoporosis treatment

基金项目:广西卫生和计划生育委员会自筹经费科研课题（Z20180721）；广西自然科学基金课题（2016GXNSFAA380058）；广西医疗卫生适宜技术开发与推广应用项目（S2018026）

作者	单位
覃永婷1 韦建勋2* 李柱海2 吴有财2	1. 广西医科大学，广西南宁 530021 2. 广西壮族自治区人民医院脊柱外科，广西南宁 530021

摘要点击次数: 1064

全文下载次数: 58

中文摘要:

骨质疏松症（osteoporosis，OP）是强直性脊柱炎（ankylosing spondylitis，AS）患者常见的合并症。OP的发生严重影响着AS患者的治疗效果及生活质量，因此，AS患者应进行OP的预防及常规治疗。目前治疗OP的主要药物有双膦酸盐、钙及维生素D等，相关研究发现，治疗AS的常规药物，如肿瘤坏死因子抑制剂（tumor necrosis factor inhibitor，TNFi）、甲状旁腺素（parathyroid hormone，PTH）、非甾体抗炎药、IL-17(interleckin-17，IL-17）阻断剂等，在OP的治疗中也发挥一定的作用，当合并骨折时，手术是首要的治疗方式。目前的研究主要集中在AS的发病机制，对合并OP的AS患者的治疗研究较少，因此，笔者综述了AS患者合并OP的相关治疗方式，并对其存在的问题和未来发展方向进行探讨。

英文摘要:

Osteoporosis (OP) is a common complication of Ankylosing Spondylitis (AS). OP is characterized by reduced bone mass and microstructure damage, and fracture is more likely to occur when bone brittleness increases. The occurrence of OP seriously affects the treatment effect and quality of life of patients with AS. Therefore, prevention and routine treatment of OP should be carried out for patients with AS. At present, the main drugs for the treatment of OP are double phosphate, calcium and vitamin D, etc. related studies have found that conventional drugs for the treatment of the AS, such AS Tumor necrosis factor inhibitor (tumor necrosis factor inhibitor, TNFi), non-steroidal anti-inflammatory drugs, IL-17 (interleckin-17, IL-17) blockers, etc. also play a role in the treatment of OP, when combined fracture surgery is the primary treatment.Current studies mainly focus on the pathogenesis of AS, and there are few studies on the treatment of patients with AS combined with OP. Therefore, the author summarizes the relevant treatment methods for patients with AS combined with OP, and discusses the existing problems and future development direction.

查看全文查看/发表评论下载PDF阅读器

关闭